SANNV Stock Overview
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 5/6 |
Sanofi Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €91.00 |
52 Week High | €98.00 |
52 Week Low | €81.80 |
Beta | 0.45 |
1 Month Change | 3.41% |
3 Month Change | -0.066% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 1.38% |
Recent News & Updates
Recent updates
Shareholder Returns
SANNV | FR Pharmaceuticals | FR Market | |
---|---|---|---|
7D | 3.4% | 5.4% | -1.3% |
1Y | n/a | -4.5% | 2.9% |
Return vs Industry: Insufficient data to determine how SANNV performed against the French Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SANNV performed against the French Market.
Price Volatility
SANNV volatility | |
---|---|
SANNV Average Weekly Movement | 4.5% |
Pharmaceuticals Industry Average Movement | 3.7% |
Market Average Movement | 4.5% |
10% most volatile stocks in FR Market | 9.1% |
10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: SANNV has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SANNV's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 86,088 | Paul Hudson | www.sanofi.com |
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Sanofi Fundamentals Summary
SANNV fundamental statistics | |
---|---|
Market cap | €116.22b |
Earnings (TTM) | €4.54b |
Revenue (TTM) | €46.29b |
25.6x
P/E Ratio2.5x
P/S RatioIs SANNV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SANNV income statement (TTM) | |
---|---|
Revenue | €46.29b |
Cost of Revenue | €14.58b |
Gross Profit | €31.71b |
Other Expenses | €27.17b |
Earnings | €4.54b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 25, 2024
Earnings per share (EPS) | 3.63 |
Gross Margin | 68.51% |
Net Profit Margin | 9.80% |
Debt/Equity Ratio | 24.8% |
How did SANNV perform over the long term?
See historical performance and comparison